Comments for TB R&D Matters Blog

Comment on Interview with Dr. Lee Reichman – Part Two by Working Group on New TB Drugs

Working Group on New TB Drugs — Fri, 03 Sep 2010 14:16:40 +0000

[...] Interview with Dr. Lee Reichman – Part Two 3 Sep 2010by Working Group Posted in TB Prevention and Control Strategies, Video, Voices from [...]

Comment on Interview with Dr. Lee Reichman – Part One by Working Group on New TB Drugs

Working Group on New TB Drugs — Fri, 03 Sep 2010 14:15:35 +0000

[...] which was recorded on June 9, 2010 at the Global Tuberculosis Institute in Newark, NJ. > click here to view part one. >click here to view part two Dr. Lee [...]

Comment on Interview with Dr. Lee Reichman – Part One by Working Group on New TB Drugs

Working Group on New TB Drugs — Thu, 26 Aug 2010 17:01:56 +0000

[...] which was recorded on June 9, 2010 at the Global Tuberculosis Institute in Newark, NJ. > click here to view part one. Dr. Lee [...]

Comment on Viewpoint: We Need New TB Drugs – Part One by Working Group on New TB Drugs

Working Group on New TB Drugs — Thu, 19 Aug 2010 13:38:32 +0000

[...] Last week, Dr. Kaiser shared his thoughts and perspectives as a medical doctor on the current state of TB drug regimens. This week he shares specific ideas on how TB drug R&D could be improved. [...]

Comment on The Sanatorium Files Part One: Timeline by Working Group on New TB Drugs

Working Group on New TB Drugs — Tue, 17 Aug 2010 15:00:52 +0000

[...] It is a moral and public health imperative that dangerous communicable diseases like tuberculosis be treated, first because of the disease’s tendency to disproportionately affect those who are least able to be treated, and second because of its potentially serious impact on those around them who are exposed and may themselves acquire latent or active disease. The ability to do so effectively is slowly becoming more and more undermined by a limited selection of drugs and an onerous baseline regimen that has not significantly changed in decades. [...]

Comment on The Sanatorium Files: Part 4 – DOTS by Working Group on New TB Drugs

Working Group on New TB Drugs — Thu, 12 Aug 2010 20:46:03 +0000

[...] our overworked department staff to put out thousands and thousands of worker-hours monthly in both directly observed therapy contacts plus innumerable phone messages to make sure that medications get to patients, are taken [...]

Comment on Launch of the Critical Path to TB Drug Regimens by Working Group on New TB Drugs

Working Group on New TB Drugs — Wed, 11 Aug 2010 14:28:38 +0000

[...] this compound be considered in the CPTR initiative to identify novel TB drug regimens? What potential liabilities if any can be predicted since the [...]

Comment on GlaxoSmithKline Finds Compound That Could Help Fight ‘Superbugs’ by Working Group on New TB Drugs

Working Group on New TB Drugs — Wed, 11 Aug 2010 13:52:55 +0000

[...] GlaxoSmithKline Finds Compound That Could Help Fight ‘Superbugs’ 11 Aug 2010by Working Group Posted in Front Lines of TB R&D, UncategorizedTags: cptr, GSK, [...]

Comment on The Sanatorium Files Part 2: The Diagnosis Dilemma by Working Group on New TB Drugs

Working Group on New TB Drugs — Thu, 05 Aug 2010 18:00:04 +0000

[...] all children in Sweden are vaccinated against TB, which causes a positive skin test for life (see The Diagnosis Dilemma post for more on the vaccine). The test result was indeed positive. Though I explained that I [...]

Comment on The Sanatorium Files Part One: Timeline by Working Group on New TB Drugs

Working Group on New TB Drugs — Thu, 05 Aug 2010 16:20:57 +0000

[...] had first-hand experience taking standard tuberculosis drugs, which were developed and approved more than 40 years ago. As the Working Group for New TB Drugs works with today’s researchers to develop better [...]